ADC Capital Expenditures vs End Period Cash Flow Analysis

ADCT Stock

USD 2.26 0.04 1.80%

ADC Therapeutics financial indicator trend analysis is way more than just evaluating ADC Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ADC Therapeutics is a good investment. Please check the relationship between ADC Therapeutics Capital Expenditures and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADC Therapeutics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Capital Expenditures vs End Period Cash Flow

Capital Expenditures vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ADC Therapeutics Capital Expenditures account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between ADC Therapeutics' Capital Expenditures and End Period Cash Flow is 0.65. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of ADC Therapeutics SA, assuming nothing else is changed. The correlation between historical values of ADC Therapeutics' Capital Expenditures and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of ADC Therapeutics SA are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Capital Expenditures i.e., ADC Therapeutics' Capital Expenditures and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by ADC Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of ADC Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

End Period Cash Flow

Most indicators from ADC Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ADC Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADC Therapeutics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

At this time, ADC Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.13 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.66 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.6M	2.4M	3.3M	2.7M
Interest Income	66K	18.0M	6.6M	5.0M

Depreciation And Amortization Interest Income

ADC Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Common Stock Total Equity	Common Stock Shares Outstanding
Total Assets		0.87	0.88	-0.02	0.67	0.48	-0.81	-0.77	0.76	0.97	0.93	0.84	0.97	0.67	0.79	0.89	0.88	0.81	1.0	0.81	0.82	0.85	-0.29	0.74	0.81	0.77
Other Current Liab	0.87		1.0	-0.36	0.82	0.66	-0.45	-0.9	0.9	0.76	0.83	0.99	0.76	0.87	0.88	0.98	0.95	0.9	0.86	0.95	0.92	0.59	-0.65	0.76	0.87	0.91
Total Current Liabilities	0.88	1.0		-0.34	0.8	0.68	-0.47	-0.89	0.9	0.77	0.84	0.99	0.77	0.88	0.88	0.97	0.94	0.9	0.87	0.93	0.89	0.58	-0.64	0.78	0.84	0.9
Total Stockholder Equity	-0.02	-0.36	-0.34		-0.71	-0.76	-0.49	0.6	-0.48	0.07	0.15	-0.4	0.07	-0.33	-0.63	-0.31	-0.33	-0.61	-0.03	-0.4	-0.35	0.15	0.78	0.04	-0.44	-0.57
Property Plant And Equipment Net	0.67	0.82	0.8	-0.71		0.77	-0.22	-0.97	0.83	0.61	0.5	0.85	0.61	0.59	0.96	0.78	0.85	0.96	0.68	0.87	0.85	0.5	-0.77	0.39	0.93	0.94
Current Deferred Revenue	0.48	0.66	0.68	-0.76	0.77		0.0	-0.72	0.77	0.38	0.3	0.67	0.38	0.66	0.83	0.63	0.55	0.83	0.49	0.59	0.48	0.09	-0.71	0.47	0.54	0.74
Net Debt	-0.81	-0.45	-0.47	-0.49	-0.22	0.0		0.34	-0.39	-0.9	-0.76	-0.41	-0.9	-0.19	-0.35	-0.49	-0.54	-0.36	-0.82	-0.45	-0.48	-0.86	-0.24	-0.46	-0.46	-0.32
Retained Earnings	-0.77	-0.9	-0.89	0.6	-0.97	-0.72	0.34		-0.89	-0.71	-0.62	-0.92	-0.71	-0.67	-0.97	-0.86	-0.94	-0.97	-0.78	-0.93	-0.91	-0.6	0.73	-0.46	-0.95	-0.94
Accounts Payable	0.76	0.9	0.9	-0.48	0.83	0.77	-0.39	-0.89		0.69	0.62	0.91	0.69	0.69	0.87	0.83	0.9	0.88	0.77	0.93	0.82	0.46	-0.7	0.57	0.77	0.85
Cash	0.97	0.76	0.77	0.07	0.61	0.38	-0.9	-0.71	0.69		0.86	0.72	1.0	0.49	0.72	0.79	0.82	0.73	0.98	0.74	0.76	0.9	-0.15	0.6	0.76	0.68
Non Current Assets Total	0.93	0.83	0.84	0.15	0.5	0.3	-0.76	-0.62	0.62	0.86		0.8	0.86	0.71	0.62	0.85	0.78	0.65	0.91	0.74	0.76	0.76	-0.25	0.87	0.7	0.66
Non Currrent Assets Other	0.84	0.99	0.99	-0.4	0.85	0.67	-0.41	-0.92	0.91	0.72	0.8		0.72	0.85	0.88	0.95	0.95	0.9	0.83	0.96	0.93	0.55	-0.72	0.73	0.88	0.93
Cash And Short Term Investments	0.97	0.76	0.77	0.07	0.61	0.38	-0.9	-0.71	0.69	1.0	0.86	0.72		0.49	0.72	0.79	0.82	0.73	0.98	0.74	0.76	0.9	-0.15	0.6	0.76	0.68
Net Receivables	0.67	0.87	0.88	-0.33	0.59	0.66	-0.19	-0.67	0.69	0.49	0.71	0.85	0.49		0.7	0.88	0.7	0.73	0.65	0.69	0.66	0.26	-0.58	0.84	0.59	0.74
Non Current Liabilities Total	0.79	0.88	0.88	-0.63	0.96	0.83	-0.35	-0.97	0.87	0.72	0.62	0.88	0.72	0.7		0.87	0.87	1.0	0.8	0.87	0.85	0.58	-0.68	0.53	0.9	0.94
Other Current Assets	0.89	0.98	0.97	-0.31	0.78	0.63	-0.49	-0.86	0.83	0.79	0.85	0.95	0.79	0.88	0.87		0.92	0.89	0.89	0.89	0.91	0.65	-0.52	0.77	0.85	0.9
Other Stockholder Equity	0.88	0.95	0.94	-0.33	0.85	0.55	-0.54	-0.94	0.9	0.82	0.78	0.95	0.82	0.7	0.87	0.92		0.89	0.88	0.98	0.97	0.72	-0.58	0.57	0.94	0.9
Total Liab	0.81	0.9	0.9	-0.61	0.96	0.83	-0.36	-0.97	0.88	0.73	0.65	0.9	0.73	0.73	1.0	0.89	0.89		0.81	0.88	0.86	0.58	-0.68	0.56	0.91	0.95
Total Current Assets	1.0	0.86	0.87	-0.03	0.68	0.49	-0.82	-0.78	0.77	0.98	0.91	0.83	0.98	0.65	0.8	0.89	0.88	0.81		0.82	0.82	0.85	-0.27	0.7	0.81	0.77
Intangible Assets	0.81	0.95	0.93	-0.4	0.87	0.59	-0.45	-0.93	0.93	0.74	0.74	0.96	0.74	0.69	0.87	0.89	0.98	0.88	0.82		0.96	0.63	-0.68	0.58	0.91	0.91
Common Stock	0.82	0.92	0.89	-0.35	0.85	0.48	-0.48	-0.91	0.82	0.76	0.76	0.93	0.76	0.66	0.85	0.91	0.97	0.86	0.82	0.96		0.71	-0.57	0.54	0.96	0.93
Other Liab	0.85	0.59	0.58	0.15	0.5	0.09	-0.86	-0.6	0.46	0.9	0.76	0.55	0.9	0.26	0.58	0.65	0.72	0.58	0.85	0.63	0.71		0.02	0.36	0.74	0.54
Net Tangible Assets	-0.29	-0.65	-0.64	0.78	-0.77	-0.71	-0.24	0.73	-0.7	-0.15	-0.25	-0.72	-0.15	-0.58	-0.68	-0.52	-0.58	-0.68	-0.27	-0.68	-0.57	0.02		-0.37	-0.6	-0.69
Other Assets	0.74	0.76	0.78	0.04	0.39	0.47	-0.46	-0.46	0.57	0.6	0.87	0.73	0.6	0.84	0.53	0.77	0.57	0.56	0.7	0.58	0.54	0.36	-0.37		0.46	0.57
Common Stock Total Equity	0.81	0.87	0.84	-0.44	0.93	0.54	-0.46	-0.95	0.77	0.76	0.7	0.88	0.76	0.59	0.9	0.85	0.94	0.91	0.81	0.91	0.96	0.74	-0.6	0.46		0.93
Common Stock Shares Outstanding	0.77	0.91	0.9	-0.57	0.94	0.74	-0.32	-0.94	0.85	0.68	0.66	0.93	0.68	0.74	0.94	0.9	0.9	0.95	0.77	0.91	0.93	0.54	-0.69	0.57	0.93

Click cells to compare fundamentals

ADC Therapeutics Account Relationship Matchups

ADC Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	137.7M	513.7M	618.0M	529.2M	354.8M	375.5M
Other Current Liab	15.5M	29.4M	49.5M	68.5M	49.2M	33.3M
Total Current Liabilities	19.9M	40.4M	73.9M	99.0M	67.7M	48.6M
Total Stockholder Equity	111.2M	335.5M	166.1M	88.7M	(148.2M)	(140.8M)
Property Plant And Equipment Net	6.3M	4.8M	11.2M	10.0M	16.1M	16.9M
Current Deferred Revenue	1.8M	834K	149K	3.8M	4.3M	4.5M
Net Debt	(110.5M)	(397.3M)	(364.8M)	(209.1M)	(154.2M)	(161.9M)
Retained Earnings	(448.6M)	(694.9M)	(924.9M)	(1.1B)	(1.3B)	(1.3B)
Accounts Payable	3.3M	5.3M	12.1M	12.4M	15.6M	9.0M
Cash	115.6M	439.2M	466.5M	326.4M	278.6M	298.6M
Non Current Assets Total	15.1M	63.2M	92.8M	83.2M	18.5M	17.6M
Non Currrent Assets Other	368K	397K	693K	903K	711K	509.0K
Cash And Short Term Investments	115.6M	439.2M	466.5M	326.4M	278.6M	298.6M
Net Receivables	2.8M	3.1M	30.2M	73.0M	25.2M	19.8M
Liabilities And Stockholders Equity	137.7M	513.7M	618.0M	529.2M	354.8M	375.5M
Non Current Liabilities Total	6.6M	137.8M	377.9M	341.5M	435.4M	457.1M
Other Current Assets	1.7M	11.3M	17.3M	23.5M	16.3M	9.9M
Other Stockholder Equity	549.8M	981.1M	981.7M	1.2B	1.2B	827.5M
Total Liab	26.5M	178.2M	451.9M	440.4M	503.0M	528.2M
Total Current Assets	122.6M	450.5M	525.2M	446.0M	336.3M	335.4M
Accumulated Other Comprehensive Income	5.5M	43.0M	102.8M	155.3M	(93K)	(88.4K)
Intangible Assets	8.4M	10.2M	13.6M	14.4M	16.5M	9.7M
Common Stock	4.4M	6.3M	6.4M	7.3M	8.4M	4.5M
Other Liab	2.7M	100.5M	65.1M	25.3M	29.1M	36.3M
Net Tangible Assets	102.7M	325.3M	153.1M	75.3M	67.8M	64.4M
Other Assets	368K	397K	27.4M	28.6M	1.0	0.95
Common Stock Shares Outstanding	66.9M	65.4M	76.7M	78.2M	81.7M	75.7M
Inventory	2.5M	6.5M	11.1M	18.6M	16.2M	8.9M
Net Invested Capital	111.2M	447.1M	297.8M	198.4M	(35.5M)	(33.7M)
Property Plant And Equipment Gross	6.3M	4.8M	11.2M	15.9M	20.4M	21.4M
Net Working Capital	102.7M	410.0M	451.2M	347.1M	268.6M	305.5M
Property Plant Equipment	6.3M	4.8M	11.2M	10.0M	11.5M	6.4M
Capital Stock	4.4M	6.3M	6.4M	7.3M	8.4M	5.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC